Hormonal
Genetic variability in the GLP1R gene can lead to non-response to GLP-1 receptor agonists in some patients with T2DM and obesity.
Some patients with T2DM and obesity do not respond well to GLP-1 receptor agonists due to genetic factors. If you are not seeing results, genetic variability in the GLP-1 receptor might be a cause. Discuss this with your healthcare provider to explore other treatment options or lifestyle interventions.
However, some T2DM and obese patients do not achieve a desired therapeutic effect of GLP-1 receptor agonists. This could be due to the multifactorial etiologies of T2DM and obesity, but genetic variability in the GLP-1 receptor or signaling pathways also needs to be considered in non-responders to GLP-1 receptor agonists.
Why this rating
Based on various studies with inconsistent results regarding specific SNPs.
Source
Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
Jasna Klen et al. · International Journal of Molecular Sciences · 2022
DOI 10.3390/ijms23073451
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →